Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

uld be scheduled no later than mid-December 2008, based on industry guidance published by the FDA. As a result, the end of January 2009 pre-NDA meeting date has affected the company's ability to meet its previous NDA submission target date. The company intends to seek the FDA's permission to complete the submission of the rolling NDA at the pre-NDA meeting. If the FDA grants such permission or accepts the NDA for filing after the submission is completed, no inference can be made concerning the FDA's ultimate decision on whether or not to approve the NDA. It is also possible that the FDA will advise the company at the pre-NDA meeting that the FDA will not allow the company to complete the submission of its NDA.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmace
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)... , Sept. 2, 2014  MEI Pharma, Inc. ... focused on the clinical development of novel therapies ... enrollment in a randomized Phase II clinical trial ... combination with azacitidine in patients with previously untreated ... placebo-controlled, double-blind study enrolled a total of 108 ...
(Date:9/2/2014)... Sept. 2, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... three drugs in its lipid franchise were highlighted in ... (ESC) Congress in Barcelona Spain . ... designed to provide effective and safe therapeutic options to ... of one commercialized drug and several other drugs in ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 2MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 3MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5
... ... Dysmenorrhea Pain Medication, HOBOKEN, N.J., June 18 A ... periods,affecting millions of women each year, can be reduced naturally ... maritime,pine tree. The multi- center field study, published in the ...
... the Need for Testosterone Screening in At-Risk ... ... from a 12-month,international, multi-center study showed that treatment for low,testosterone with ... and sexual function among,hypogonadal men with Type 2 diabetes and/or Metabolic ...
Cached Medicine Technology:New Study: Pine Bark Significantly Reduces Menstrual Pain 2New Study: Pine Bark Significantly Reduces Menstrual Pain 3Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome 2Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome 3
(Date:9/2/2014)... News) -- The quality of Americans, diets has improved ... the rich and poor is growing, a new study ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ... doctoral student in the department of nutrition at the ...
(Date:9/2/2014)... Amy Norton HealthDay Reporter , ... want to lose weight and boost their heart health, cutting ... a new study suggests. In a small clinical trial ... a low-carbohydrate diet lost more weight over a year than ... bigger improvements in their cholesterol and triglyceride levels, the research ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... health problems outside the lungs, researchers say , , WEDNESDAY, ... and long-term toxic effects on the heart and blood ... cause death, a new report says. , The ... issue of the Journal of the American College ...
... Physician Accuracy And ... Reduces Radiation Exposure for Patients, AUSTIN, Texas, Aug. ... Institute (TCAI) at St. David,s Medical Center became,the first ... -- an enhancement to the state-of-the art Hansen Robotic ...
... ("Assurant"),(NYSE: AIZ ), a premier provider of ... that Jane Meyer,has been appointed senior vice president, ... vice president, organizational development and,corporate communications effective immediately. ... and Mr. Walker will continue to report to ...
... Daily Dietary Supplements to Introduce Fashion Week ... Survival Kit at Verrier Runway Show, ... its,first-ever fashion partnership with breakout designer Ashleigh Verrier to,promote "Style ... healthy beauty during one of the most exciting and fast-paced,fashion ...
... the National Institutes of Health (NIH) have found a mechanism ... the development of autoimmune disease when turned off. The findings ... of autoimmunity and could also have implications for the development ... as cancer and HIV. The study paper appears online today ...
... strength, agility tied to brain damage, even in the ... -- Physical frailty among the elderly may be linked ... patients develop dementia, new research reveals. , The finding, ... the notion that motor impairment in the elderly is ...
Cached Medicine News:Health News:Air Pollution Can Damage Heart, Blood Vessels, Too 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 3Health News:Assurant Announces Two Executive Appointments 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 3Health News:NIH scientists find a novel mechanism that controls the development of autoimmunity 2Health News:Physical Frailty Could Predict Alzheimer's Disease 2Health News:Physical Frailty Could Predict Alzheimer's Disease 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: